Annuaire du CSM
Dr Renaud GRÉPIN
Chargé de Recherche - Équipe Mécanismes de Résistance aux Thérapies CibléesTel. +377 97 77 44 10
Email : [javascript protected email address]
Thèmes de recherche développés
Etude des mécanismes de résistance aux traitements anti-angiogéniques dans le cancer du rein
Recherche de marqueurs prédictifs de l’efficacité des thérapies anti-angiogéniques dans ce même cancer
Bénéfices des inhibiteurs du récepteur de l'EGF dans le traitement des cancers du rein réfractaires aux anti-angiogéniques
Publications CSM
-
Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
Pagnuzzi M, Picco V, Vial V, Planas-Bielsa V, Vandenberghe A, Daubon T, Derieppe M-A, Montemagno C, Durivault J, Grépin R, Martial S, Doyen J, Gavard J, Pagès G
Cancers 14(1) : 70 -
Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti- angiogenic therapy
Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grépin R, Rioux-Leclercq N, Bernhard J-C, Pagès G, Dufies M
BJU Int 2022 Jan;129(1):80-92 -
Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas
Dumond A, Montemagno C, Vial V, Grépin R, Pagès G
Cells 10(5): 1222 -
Cancer associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to antiangiogenic therapy
Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grépin R, Rioux-Leclercq N, Bernhard J-C, Pagès G, Dufies M
BJU Int doi: 10.1111/bju.15506. -
Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
Dumond A, Brachet E, Durivault J, Vial V, Puszko A K, Lepelletier Y, Montemagno C, Pagnuzzi M, Hermine O, Garbay C, Lagarde N, Montes M, Demange L, Grépin R, Pagès G
J Exp Clinical Cancer Research 40: 33 -
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor
Grépin R, Guyot M, Dumond A, Durivault J, Ambrosetti D, Roussel J F, Dupré F, Quintens H, Pagès G
Theranostics 10(3): 1107-1121 -
New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments
Dufies M, Grytsai O, Ronco C, Camara O, Ambrosetti D, Hagege A, Parola J, Mateo L, Ayrault M, Giuliano S, Grépin R, Lagarde N, Montes M, Auberger P, Demange L, Benhida R, Pagès G
Theranostics 9(18): 5332–5346 -
VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness
Ndiaye P D, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G
Theranostics 9(3): 661-675 -
Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma
Dufies M, Nollet M, Ambrosetti D, Traboulsi W, Viotti J, Borchiellini D, Grépin R, Parola J, Giuliano S, Helley-Russick D, Bensalah K, Ravaud A, Bernhard J C, Schiappa R, Bardin N, Dignat-George F, Rioux-Leclercq N, Oudard S, Négrier S, Ferrero J M, Chamorey E, Blot-Chabaud M, Pagès G
Theranostics 8(9): 2447-2458 -
CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
Dufies M, Giuliano S, Viotti J, Borchiellini D, Cooley L S, Ambrosetti D, Guyot M, Ndiaye P D, Parola J, Claren A, Schiappa R, Gal J, Frangeul A, Jacques A, Cassuto O, Grépin R, Auberger P, Bikfalvi A, Milano G, Escudier B, Rioux-Leclercq N, Porta C, Negrier S, Chamorey E, Ferrero J M, Pagès G
Br J Cancer 117(7): 947-953 -
NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model
Liu W-Q, Lepelletier Y, Montes M, Borriello L, Jarray R, Grépin R, Leforban B, Loukaci A, Benhida R, Hermine O, Dufour S, Pagès G, Garbay C, Raynaud F, Hadj-Slimane R, Demange L
Can Let 414: 88-98 -
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.
Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye P D, Mastri M, Moghrabi W, Cooley L S, Ettaiche M, Chamorey E, Parola J, Vial V, Lupus-Plesu M, Bernhard J C, Ravaud A, Borchiellini D, Ferrero J M, Bikfalvi A, Ebos J M, Khabar K S, Grépin R, Pagès G
Cancer Res 77(5): 1-15 -
Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies
Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G
Oncotarget 8(6): 9174-9188 -
Lebein, a snake venom disintegrin, suppresses human colon cancer cells proliferation and tumor-induced angiogenesis through cell cycle arrest, apoptosis induction and inhibition of VEGF expression.
Zakraoui O, Marcinkiewicz C, Aloui Z, Othman H, Grépin R, Haoues M, Essafi M, Srairi-Abid N, Gasmi A, Karoui H, Pagès G, Essafi-Benkhadir K
Mol Carcinog 56(1): 18-35 -
Systematic analysis of AU-rich element expression in cancer reveals common functional clusters regulated by key RNA-binding proteins.
Hitti E, Bakheet T, Al-Souhibani N, Moghrabi W, Al-Yahya S, Al-Ghamdi M, Al-Saif M, Shoukri M M, Lanczk A, Grépin R, Gyorffy B, Pagès G, Khabar K S
Cancer Res 76(14): 4068-4080 -
Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux
Giuliano S, Cormerais Y, Dufies M, Grépin R, Colosetti P, Belaid A, Parola J, Martin A, Lacas-Gervais S, Mazure N M, Benhida R, Auberger P, Mograbi B, Pagès G
Autophagy 11(10): 1891-1904 -
Resistance to Antiangiogenic Treatments via Upregulation of Substitution Pathways
Grépin R, Guyot M, Pagès G
Molecular Mechanisms of Angiogenesis Springer Paris, Chap. 20: 397-419 -
The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma
Grépin R, Guyot M, Giuliano S, Pagnuzzi M, Ambrosetti D, Chamorey E, Scoazec J Y, Negrier S, Simonnet H, Pagès G
Cancer Res 74(3): 873-883 -
The ELRCXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma
Giuliano S, Guyot M, Grépin R, Pagès G
Oncoimmunology 3: e28399 -
The Relevance of Testing the Efficacy of Anti-Angiogenesis Treatments on Cells Derived from Primary Tumors: A New Method for the Personalized Treatment of Renal Cell Carcinoma
Grépin R, Ambrosetti D, Marsaud A, Gastaud L, Amiel J, Pedeutour F, Pagès G
PLoS ONE 9(3): e89449